Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2 trial of Orca-T in patients with acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes, myelofibrosis and other hematological malignancies

Next Previous
X
Search
Trial Profile

Phase 1b/2 trial of Orca-T in patients with acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes, myelofibrosis and other hematological malignancies

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orca-T (Primary)
  • Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Myelofibrosis; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 Oct 2022 Results reporting safety and efficacy of Orca-T in patients with hematologic malignancies who received Orca-T in a single-center Phase 1/2 study (NCT01660607) and a multicenter Phase 1b study (NCT04013685) published in the Clinical Lymphoma, Myeloma & Leukemia
    • 17 Dec 2021 New trial record
    • 11 Dec 2021 According to an Orca Bio media release, positive pooled results from single-center Phase 2 and multi-center Phase 1b trials from 109 patients were presented at the 63rd American Society of Hematology (ASH) Annual Meeting 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top